A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy-Reference-Cited by-同舟云学术

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Published:2016-01 Issue:1 Volume:29 Page:117-129
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Li John Y.,Perry Samuel R.,Muniz-Medina Vanessa,Wang Xinzhong,Wetzel Leslie K.,Rebelatto Marlon C.,Hinrichs Mary Jane Masson,Bezabeh Binyam Z.,Fleming Ryan L.,Dimasi Nazzareno,Feng Hui,Toader Dorin,Yuan Andy Q.,Xu Lan,Lin Jia,Gao Changshou,Wu Herren,Dixit Rakesh,Osbourn Jane K.,Coats Steven R.

Funder

MedImmune LLC

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference39 articles.

1. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin;Austin;Mol. Biol. Cell,2004

2. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis;Ben-Kasus;Proc. Natl. Acad. Sci. USA,2009

3. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling;Boersma;J. Biol. Chem.,2011

4. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy;Burris;J. Clin. Oncol.,2011

5. Human Antibodies to ErbB2;Cartilage,2010

Cited by 287 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

3. Emerging magic bullet: subcellular organelle-targeted cancer therapy;Medical Review;2024-09-12

4. Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy;Drug Discovery Today;2024-09

5. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs;World Journal of Oncology;2024-08